Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1186/s12929-017-0377-1 http://scihub22266oqcxt.onion/10.1186/s12929-017-0377-1 C5591517!5591517!28886718     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=28886718&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       J+Biomed+Sci 2017 ; 24 (ä): ä Nephropedia Template TP {{tp|p=28886718|t=2017. Repositioning drugs for traumatic brain injury - N-acetyl cysteine and Phenserine |pdf=|usr=}}{{28886718}} gab.com Text Repositioning drugs for traumatic brain injury - N-acetyl cysteine and Phenserine JO: J Biomed Sci http://www.kidney.de/pget.php?&tw=1&pmid=28886718 #FOAvip Traumatic brain injury (TBI) is one of the most common causes of morbidity and mortality of both young adults of less than 45 years of age and the elderly, and contributes to about 30% of all injury deaths in the United States of America. Whereas there has been a significant improvement in our understanding of the mechanism that underpin the primary and secondary stages of damage associated with a TBI incident, to date however, this knowledge has not translated into the development of effective new pharmacological TBI treatment strategies. Prior experimental and clinical studies of drugs working via a single mechanism only may have failed to address the full range of pathologies that lead to the neuronal loss and cognitive impairment evident in TBI and other disorders. The present review focuses on two drugs with the potential to benefit multiple pathways considered important in TBI. Notably, both agents have already been developed into human studies for other conditions, and thus have the potential to be rapidly repositioned as TBI therapies. The first is N-acetyl cysteine (NAC) that is currently used in over the counter medications for its anti-inflammatory properties. The second is (?)-phenserine ((?)-Phen) that was originally developed as an experimental Alzheimer?s disease (AD) drug. We briefly review background information about TBI and subsequently review literature suggesting that NAC and (?)-Phen may be useful therapeutic approaches for TBI, for which there are no currently approved drugs. Twit Text FOAVip Repositioning drugs for traumatic brain injury - N-acetyl cysteine and Phenserine ????J Biomed Sci http://www.kidney.de/pget.php?&tw=1&pmid=28886718 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=28886718 #FOAvip English Wikipedia <ref>{{Cite pmid|28886718}}</ref> Repositioning drugs for traumatic brain injury - N-acetyl cysteine and Phenserine #MMPMID28886718 Hoffer BJ; Pick CG; Hoffer ME; Becker RE; Chiang YH; Greig NH J Biomed Sci 2017[]; 24 (ä): ä PMID28886718show ga Traumatic brain injury (TBI) is one of the most common causes of morbidity and mortality of both young adults of less than 45 years of age and the elderly, and contributes to about 30% of all injury deaths in the United States of America. Whereas there has been a significant improvement in our understanding of the mechanism that underpin the primary and secondary stages of damage associated with a TBI incident, to date however, this knowledge has not translated into the development of effective new pharmacological TBI treatment strategies. Prior experimental and clinical studies of drugs working via a single mechanism only may have failed to address the full range of pathologies that lead to the neuronal loss and cognitive impairment evident in TBI and other disorders. The present review focuses on two drugs with the potential to benefit multiple pathways considered important in TBI. Notably, both agents have already been developed into human studies for other conditions, and thus have the potential to be rapidly repositioned as TBI therapies. The first is N-acetyl cysteine (NAC) that is currently used in over the counter medications for its anti-inflammatory properties. The second is (?)-phenserine ((?)-Phen) that was originally developed as an experimental Alzheimer?s disease (AD) drug. We briefly review background information about TBI and subsequently review literature suggesting that NAC and (?)-Phen may be useful therapeutic approaches for TBI, for which there are no currently approved drugs. äRepositioning drugs for traumatic brain injury - N-acetyl cysteine and(epmc).pdf DeepDyve Pubget Overpricing